These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 33836635)
21. Clonal selection in therapy-related myelodysplastic syndromes and acute myeloid leukemia under azacitidine treatment. Calleja A; Yun S; Moreilhon C; Karsenti JM; Gastaud L; Mannone L; Komrokji R; Al Ali N; Dadone-Montaudie B; Robert G; Auberger P; Raynaud S; Sallman DA; Cluzeau T Eur J Haematol; 2020 May; 104(5):488-498. PubMed ID: 31990086 [TBL] [Abstract][Full Text] [Related]
22. Use of hypomethylating agents in myelodysplastic syndromes. Atallah E; Garcia-Manero G Clin Adv Hematol Oncol; 2007 Jul; 5(7):544-52. PubMed ID: 17679928 [TBL] [Abstract][Full Text] [Related]
23. Current status of epigenetic treatment in myelodysplastic syndromes. Kuendgen A; Lübbert M Ann Hematol; 2008 Aug; 87(8):601-11. PubMed ID: 18392623 [TBL] [Abstract][Full Text] [Related]
24. More is better: combination therapies for myelodysplastic syndromes. Ornstein MC; Mukherjee S; Sekeres MA Best Pract Res Clin Haematol; 2015 Mar; 28(1):22-31. PubMed ID: 25659727 [TBL] [Abstract][Full Text] [Related]
25. Efficacy and safety of azacitidine in pediatric patients with newly diagnosed advanced myelodysplastic syndromes before hematopoietic stem cell transplantation in the AZA-JMML-001 trial. Locatelli F; Strålin KB; Schmid I; Sevilla J; Smith OP; van den Heuvel-Eibrink MM; Zecca M; Zwaan CM; Gaudy A; Patturajan M; Poon J; Simcock M; Niemeyer CM Pediatr Blood Cancer; 2024 May; 71(5):e30931. PubMed ID: 38433307 [TBL] [Abstract][Full Text] [Related]
26. Azacitidine for myelodysplastic patients aged > 65 years: a review of clinical efficacy. Breccia M; Molica M; Zacheo I; Alimena G Expert Opin Pharmacother; 2014 Aug; 15(11):1621-30. PubMed ID: 24989987 [TBL] [Abstract][Full Text] [Related]
27. Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905. Prebet T; Sun Z; Figueroa ME; Ketterling R; Melnick A; Greenberg PL; Herman J; Juckett M; Smith MR; Malick L; Paietta E; Czader M; Litzow M; Gabrilove J; Erba HP; Gore SD; Tallman MS J Clin Oncol; 2014 Apr; 32(12):1242-8. PubMed ID: 24663049 [TBL] [Abstract][Full Text] [Related]
28. A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome. Kirschbaum M; Gojo I; Goldberg SL; Bredeson C; Kujawski LA; Yang A; Marks P; Frankel P; Sun X; Tosolini A; Eid JE; Lubiniecki GM; Issa JP Br J Haematol; 2014 Oct; 167(2):185-93. PubMed ID: 25040094 [TBL] [Abstract][Full Text] [Related]
29. Transcription factors implicated in late megakaryopoiesis as markers of outcome after azacitidine and allogeneic stem cell transplantation in myelodysplastic syndrome. Falconi G; Fabiani E; Criscuolo M; Fianchi L; Finelli C; Cerqui E; Pelosi E; Screnci M; Gurnari C; Zangrilli I; Postorino M; Laurenti L; Piciocchi A; Testa U; Lo-Coco F; Voso MT Leuk Res; 2019 Sep; 84():106191. PubMed ID: 31386932 [TBL] [Abstract][Full Text] [Related]
30. A call for action: Increasing enrollment of untreated patients with higher-risk myelodysplastic syndromes in first-line clinical trials. Zeidan AM; Stahl M; Sekeres MA; Steensma DP; Komrokji RS; Gore SD Cancer; 2017 Oct; 123(19):3662-3672. PubMed ID: 28759108 [TBL] [Abstract][Full Text] [Related]
31. Clinical experience with decitabine in North American patients with myelodysplastic syndrome. Yee KW; Jabbour E; Kantarjian HM; Giles FJ Ann Hematol; 2005 Dec; 84 Suppl 1():18-24. PubMed ID: 16273408 [TBL] [Abstract][Full Text] [Related]
32. Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study. Prebet T; Sun Z; Ketterling RP; Zeidan A; Greenberg P; Herman J; Juckett M; Smith MR; Malick L; Paietta E; Czader M; Figueroa M; Gabrilove J; Erba HP; Tallman MS; Litzow M; Gore SD; Br J Haematol; 2016 Feb; 172(3):384-91. PubMed ID: 26577691 [TBL] [Abstract][Full Text] [Related]
33. Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS. Gerds AT; Gooley TA; Estey EH; Appelbaum FR; Deeg HJ; Scott BL Biol Blood Marrow Transplant; 2012 Aug; 18(8):1211-8. PubMed ID: 22252125 [TBL] [Abstract][Full Text] [Related]
34. Overall survival of myelodysplastic syndrome patients after azacitidine discontinuation and applicability of the North American MDS Consortium scoring system in clinical practice. Clavio M; Crisà E; Miglino M; Guolo F; Ceccarelli M; Salvi F; Allione B; Ferrero D; Balleari E; Finelli C; Poloni A; Selleri C; Danise P; Cilloni D; Di Tucci AA; Cametti G; Freilone R; Fanin R; Bigazzi C; Zambello R; Crugnola M; Oliva EN; Centurioni R; Alesiani F; Catarini M; Castelli A; Abbadessa A; Capalbo SF; Musto P; Angelucci E; Santini V Cancer; 2021 Jun; 127(12):2015-2024. PubMed ID: 33739457 [TBL] [Abstract][Full Text] [Related]
35. The Hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and acute myeloid leukemia. Tibes R; Al-Kali A; Oliver GR; Delman DH; Hansen N; Bhagavatula K; Mohan J; Rakhshan F; Wood T; Foran JM; Mesa RA; Bogenberger JM J Hematol Oncol; 2015 Oct; 8():114. PubMed ID: 26483188 [TBL] [Abstract][Full Text] [Related]
39. [Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome]. Zhi YQ; Guo SQ; Zhang YZ Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Jun; 20(3):792-5. PubMed ID: 22739204 [TBL] [Abstract][Full Text] [Related]
40. The emerging role of immune checkpoint based approaches in AML and MDS. Boddu P; Kantarjian H; Garcia-Manero G; Allison J; Sharma P; Daver N Leuk Lymphoma; 2018 Apr; 59(4):790-802. PubMed ID: 28679300 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]